XNAS · Healthcare · Biotechnology
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.66 | -0.74 | -12.12% | $0 | ❌ Miss | +0.78% | +5.68% | — |
| 2026-02-19 | Q4 2025 | -0.74 | -0.70 | +5.41% | $0 | ✅ Beat | +0.00% | +14.12% | +9.10% |
| 2025-11-04 |
| Q3 2025 |
| -0.72 |
| -0.15 |
| +79.17% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.72 | -0.49 | +31.94% | $0 | ✅ Beat | +1.48% | -5.81% | +0.71% |
| 2025-02-27 | Q4 2024 | -0.97 | -0.81 | +16.49% | $0 | ✅ Beat | +7.24% | +11.60% | -12.17% |
| 2024-11-07 | Q3 2024 | -0.83 | -1.36 | -63.86% | $0 | ❌ Miss | +5.00% | -17.03% | -28.87% |
| 2024-08-07 | Q2 2024 | -0.95 | -0.86 | +9.47% | $0 | ✅ Beat | +2.85% | +0.73% | +13.89% |
| 2024-02-29 | Q4 2023 | -0.78 | -4.05 | -419.23% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.